One of 13 companies to receive Premier, Inc.’s Supplier Horizon Award for excellence in improving healthcare performance, HemoSonics’ Quantra Hemostasis System provides comprehensive hemostasis analysis in less than 15 minutes

HemoSonics LLC, a medical device company focused on acute bleeding management, today announced it has won the 2025 Supplier Horizon Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. HemoSonics was honored for its Quantra Hemostasis System, an advanced viscoelastic testing device that accelerates decision-making, enhances patient outcomes and reduces healthcare costs by delivering rapid, actionable coagulation assessments in near real-time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717969423/en/

HemoSonics’ Quantra System is FDA-cleared for use in cardiovascular and major orthopedic surgery, trauma, and liver transplantation. Quantra requires minimal resources to maintain. It's easy to operate and interpret results, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. The Quantra Hemostasis System technology has received numerous accolades, including the 2025 Supplier Horizon Award from Premier, Inc., Triangle Business Journal's 2025 Life Sciences Award for Best Medical Device Company, 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America.

One of 13 suppliers to receive the award this year, HemoSonics was recognized for its support of Premier members through exceptional local customer service and engagement, as well as value creation through clinical excellence and a commitment to lower costs. Supplier Horizon Award winners are selected by Premier member committees and have a tenure of less than three years as a Premier contracted supplier.

HemoSonics’ Quantra Hemostasis System comprises the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges. The Quantra System utilizes innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound technology that measures the coagulation properties of a whole blood sample, providing comprehensive coagulation analysis in under 15 minutes. Doctors receive test results quickly during critical and complex surgeries, enabling timely, patient-centered decisions about bleeding management, which improves care and optimizes the use of blood products.

“Our mission is to ensure that our clinician partners receive accurate test results quickly during critical, complex surgeries that allow them to make timely patient-centered clinical decisions. By doing so, patients can receive the care that they need at the moment that they need it. We will continue to work tirelessly to ensure that our customers and partners are supported, as we partner with hospitals to deliver better patient outcomes, all while lowering the cost of care,” said HemoSonics President and CEO Bob Roda. “We are humbled and proud to receive the Supplier Horizon Award from Premier, Inc.”

HemoSonics’ Quantra System is FDA-cleared for use in cardiovascular and major orthopedic surgery, trauma, and liver transplantation. It requires minimal resources to maintain, is easy to operate and interpret results, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. According to a 2023 Journal of Cardiothoracic Surgery study, Quantra reduced blood component use between 10% and >90%. In addition, the cost of blood products decreased by 41%.

“HemoSonics supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value,” said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. “We’re honored to recognize HemoSonics as a Supplier Horizon Award recipient.”

The Supplier Horizon Award recipients were honored during Premier’s annual Breakthroughs Conference & Exhibition, July 15-17, 2025.

About HemoSonics

HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's ease of use and fast interpretation of results enable simple, more efficient point-of-care and laboratory bleeding management.

Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Follow HemoSonics on LinkedIn or visit HemoSonics.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250717969423/en/

Our mission is to ensure that our clinician partners receive accurate test results quickly during critical, complex surgeries that allow them to make timely patient-centered clinical decisions.